EQS-Adhoc: BB Biotech AG closes the 2025 fiscal year with a profit

Ad hoc announcement pursuant to Art. 53 LR

January 23, 2026

BB Biotech AG closes the 2025 fiscal year with a profit

In accordance with regulations on ad hoc publicity, BB Biotech AG (ISIN CH0038389992) is releasing the following information:

Based on its preliminary unaudited consolidated figures, BB Biotech AG reports a profit of approximately CHF 578 mn for the financial year 2025 (profit of CHF 76 mn in the previous year). For an investment company, the results reflect the share price development of the companies held in the portfolio.

The publication of all relevant portfolio data and the complete annual report will take place on February 20, 2026.

For further information:
Bellevue Asset Management AG
Theaterstrasse 12, 8001 Zurich, Switzerland, tel. +41 44 267 67 00

Head BB Biotech
Dr. Christian Koch

Investor Relations
Rachael Burri, rbu@bellevue.ch

E-Mail: ir@bbbiotech.com
Phone: +41 44 267 67 17

Media Relations
Tanja Chicherio, tch@bellevue.ch

www.bbbiotech.com

Company profile  
BB Biotech AG is an investment company with its registered office in Schaffhausen/Switzerland and listed on the Swiss and German stock exchanges. It has invested in innovative drug developers headquartered primarily in the US and Western Europe. BB Biotech is one of the world’s largest investors in this sector. The competent Board of Directors with its long-standing experience set the investment strategy and guidelines. Investment decisions are taken by the experienced investment management team of Bellevue Asset Management AG based on their extensive investment research.